Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2017-10-16 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于控股股东股权质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's controlling shareholder. It details the number of shares pledged, the pledge period, the pledgee, and the impact on shareholding percentages. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about a shareholder's share pledge, which fits the category of Regulatory Filings (RNS) as it does not fall under more specific categories like Major Shareholding Notification (MRQ) or Director's Dealing (DIRS). The document length is short and it is an announcement, not a report or detailed filing.
2017-10-16 Chinese
关于全资子公司与惠州大亚湾区政府置换土地使用权的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of land use rights exchange involving a wholly-owned subsidiary and a government entity. It includes details about the land location, usage, rights, and certificates obtained. The document is relatively short (943 characters) and focuses on a specific transaction update rather than financial results, management changes, or regulatory certifications. It does not contain financial statements or detailed financial data. The content fits best under a general regulatory announcement category rather than a detailed financial report or management disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2017-08-25 Chinese
独立董事关于公司有关事项所发表的独立意见
Board/Management Information Classification · 90% confidence The document is an independent director's statement regarding several company matters, including the use of idle funds for bank wealth management products, the reappointment of the 2017 audit firm, and opinions on external guarantees and related party fund occupation. It references compliance with company law and stock exchange listing rules, and it is dated August 24, 2017. The document does not contain financial statements or detailed audit results but rather expresses independent opinions on company governance and financial practices. It is not a full audit report or annual report but an independent director's opinion document related to governance and oversight. This fits best under Board/Management Information (MANG) as it relates to governance and oversight opinions by independent directors rather than a full audit report or financial report.
2017-08-24 Chinese
第四届监事会第五次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. It discusses the approval of the company's 2017 semi-annual report and related financial matters, including the use of idle funds for investment in low-risk bank financial products. The document is relatively short (1255 characters) and primarily serves as an official announcement of the Supervisory Board's meeting decisions rather than the full semi-annual report itself. It references the semi-annual report and where it can be found but does not contain the full financial statements or detailed analysis. Therefore, it is not the Interim/Quarterly Report (IR) itself but an announcement related to it. Given the nature and length, this fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2017-08-24 Chinese
关于使用自有闲置资金投资银行理财产品的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by Shenzhen Xinlitai Pharmaceutical Co., Ltd. regarding the use of its own idle funds to invest in low-risk short-term bank wealth management products. It includes details about the investment purpose, amount, types, risk analysis, control measures, and opinions from independent directors and the supervisory board. The document is structured as a public disclosure or announcement rather than a financial report or detailed financial statement. It does not contain comprehensive financial data or results but rather informs shareholders and the public about a specific investment decision approved by the board. The document length is 4187 characters, which is relatively short and consistent with an announcement. Therefore, it fits best into the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2017-08-24 Chinese
第四届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the Shenzhen Xinlitai Pharmaceutical Co., Ltd. Fourth Board of Directors Fifth Meeting held on August 24, 2017. It includes approval of the 2017 semi-annual report and its summary, approval of investment in bank financial products, reappointment of the audit firm for 2017, and change of the audit department head. The document contains no actual financial statements or detailed financial data but rather decisions and approvals by the board. It also references where the full semi-annual report and financial report can be found, indicating this document is not the report itself but an announcement of board resolutions including approval of the interim report. The document length is about 2905 characters, relatively short, and it serves as a meeting resolution announcement rather than a full interim report. Therefore, the best classification is Board/Management Information (MANG) as it announces board meeting decisions including management changes and approvals.
2017-08-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.